Monarch Therapeutics, Inc.

Grateful for our team at the University of Pittsburgh and our scientific co-founders Jason Lohmueller and Alex Deiters. Thank you to all involved for honoring the work of Jason and Alex and to Pitt for creating a world-class environment for translating academic research into life-changing commercial therapies! As Pat Bostick said, Hail to Possible, Hail to Pitt!

Even with the tremendous efforts at raising breast cancer research funds and awareness over the last 20 years, outcomes are far from where we all want them to be. Particularly if you are a minority. This new report from the American Cancer Society highlights that in 2024 we will see: >300,000 new breast cancer diagnosis >42,000 deaths from breast cancer >19% chance of triple-negative diagnosis for black women (compared to only 9-11% for other racial groups) At Monarch Therapeutics, Inc. we are developing the next generation of modular, personalized therapies that will allow doctors and patients to overcome these crucial differences between patients. The "differences make us, us" and now it's time for our medicines to be as diverse as we are! https://lnkd.in/eyGD_YQA

January unleashes cell therapy IPOs, 5 exciting start-ups join the scene, CGT monthly highlights below ?? ?? ?????????????????? ?????????????????? ???????? ?????????????? was the key theme for January. Tr1X launched with a strong Series A for allogenic cell therapies for autoimmune diseases and Monarch Therapeutics, Inc. arrived with an exciting solid tumour platform play + a PIVOT beyond cancer soon. ?????????????? ?????????????????? ??????????????????????????????????????????? with 7 IND approvals, 2 BLAs submitted and 5 ODDs. Huge achievement from Autolus Therapeutics with a BLA acceptance + PDUFA Goal date of 11/16/2024. ?? ???????????????????????? ???????? ???????? ?? ???????????? ?????????? for January as shown through Iaso/Umoja Biopharma in developing two ex vivo iPSC-derived CAR-bearing cell therapies as well as Precision BioSciences, Inc. striking another cell therapy licensing deal for ???????????????????????? ???????????? ????????????. Special January mention to Peter Maag, Tom Van Blarcom and the team at Kyverna Therapeutics with a strong cell therapy IPO push. #celltherapy #genetherapy #CGTweekly #biotech

Looking forward to seeing everyone in SF next week at #JPM2024. I'll be joining my good friend Matt Gardner from CBRE for a fireside chat about the cell and gene therapy field. We'll be discussing the tremendous progress the field has made even in the face of current headwinds and what the next few years hold for us. I hope you will find time to join us for an engaging conversation. https://lnkd.in/eDfzGBCF